GLP-1 Analogues in Obesity Therapy: Current Evidence and Future Directions – A Systematic Review

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review demonstrates significant weight reduction in obesity via GLP-1 receptor agonists, implying promising cardiometabolic benefits.

Treatment with liraglutide resulted in average weight reductions of 7–8% over 56 to 104 weeks, alongside improvements in metabolic parameters.
Semaglutide achieved weight losses of 14–17% in both adult and adolescent populations, offering substantial weight management options.
Tirzepatide showed unprecedented efficacy with reductions of up to 20.9% at higher doses, indicating its potential as a leading treatment for obesity.
Despite their benefits, challenges like weight regain after treatment, high costs, and the need for additional safety data remain significant concerns.

Strumnik et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Systematic review demonstrates significant weight reduction in obesity via GLP-1 receptor agonists, implying promising cardiometabolic benefits.

Treatment with liraglutide resulted in average weight reductions of 7–8% over 56 to 104 weeks, alongside improvements in metabolic parameters.
Semaglutide achieved weight losses of 14–17% in both adult and adolescent populations, offering substantial weight management options.
Tirzepatide showed unprecedented efficacy with reductions of up to 20.9% at higher doses, indicating its potential as a leading treatment for obesity.
Despite their benefits, challenges like weight regain after treatment, high costs, and the need for additional safety data remain significant concerns.

Strumnik et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark